 |
 |

Survival Effect of Lung Transplantation Among Patients With Cystic Fibrosis
Theodore G. Liou, MD;
Frederick R. Adler, PhD;
Barbara C. Cahill, MD;
Stacey C. FitzSimmons, PhD;
David Huang, DPH;
Jonathan R. Hibbs, MD;
Bruce C. Marshall, MD
JAMA. 2001;286:2683-2689.
Context Patients with cystic fibrosis (CF) are the second largest group of lung transplant recipients in the United States. The survival effect of transplantation on a general CF population has not previously been measured.
Objective To determine the impact of bilateral lung transplantation on survival in patients with CF.
Design, Setting, and Patients Retrospective observational cohort study of 11 630 CF patients who did not undergo lung transplantation (controls) and 468 transplant recipients with CF from 115 CF centers in the United States, 1992-1998. Patients were stratified into 5 groups based on a 5-year survival prediction model (survival group 1: <30%; survival group 2: 30 to <50%; survival groups 3-5: 50 to <100%.)
Main Outcome Measure Five-year survival from date of transplantation in 1992-1997 in the transplant group and from January 1, 1993, in the control group.
Results Lung transplantation increased 5-year survival of CF patients in survival group 1. Survival group 2 had equivocal survival effects, and groups 3-5 had negative survival effects from transplantation. From 1994-1997, there was a mean annual prevalence of 238 patients in survival group 1 and mean annual incidence of 154 patients entering the group, approximately 1.5 times the number of lung transplantations performed each year in CF patients (mean, 104). Use of the criterion of forced expiratory volume in 1 second of less than 30% resulted in an equivocal survival benefit and identified 1458 potential candidates for transplantation in 1993.
Conclusions Cystic fibrosis patients in group 1 have improved 5-year survival after lung transplantation. The majority of patients with CF have equivocal or negative survival effects from the procedure. Selection of patients with CF for transplantation based on group 1 survival predictions maximizes survival benefits to individuals and may reduce the demand for scarce donor organs.
Author Affiliations: Division of Respiratory, Critical Care and Occupational Pulmonary Medicine (Drs Liou, Cahill, and Marshall), Departments of Mathematics and Biology (Dr Adler), Lung Transplantation Program (Dr Cahill), and Intermountain Cystic Fibrosis Center (Drs Liou and Marshall), University of Utah, Salt Lake City; Medical Department, Cystic Fibrosis Foundation, Bethesda, Md (Dr FitzSimmons); Salt Lake Veterans Affairs Medical Center, Salt Lake City, Utah (Dr Marshall); School of Public Health, University of California, Los Angeles (Dr Huang); and the New York State Department of Health, Albany (Dr Hibbs). Dr FitzSimmons is now with FitzSimmons and Associates.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
Patient Selection for Lung Transplantation
Janet R. Maurer
JAMA. 2001;286(21):2720-2721.
EXTRACT
| FULL TEXT
December 5, 2001
JAMA. 2001;286(21):2745-2746.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Circulating RNA Transcripts Identify Therapeutic Response in Cystic Fibrosis Lung Disease
Saavedra et al.
Am. J. Respir. Crit. Care Med. 2008;178:929-938.
ABSTRACT
| FULL TEXT
Impact of Burkholderia Infection on Lung Transplantation in Cystic Fibrosis
Murray et al.
Am. J. Respir. Crit. Care Med. 2008;178:363-371.
ABSTRACT
| FULL TEXT
Determinants of the Survival Benefit of Lung Transplantation in Patients with Chronic Obstructive Pulmonary Disease
Thabut et al.
Am. J. Respir. Crit. Care Med. 2008;177:1156-1163.
ABSTRACT
| FULL TEXT
Lung Transplantation and Survival in Children with Cystic Fibrosis
Liou et al.
NEJM 2007;357:2143-2152.
ABSTRACT
| FULL TEXT
Lung Transplantation in Cystic Fibrosis -- Primum Non Nocere?
Allen and Visner
NEJM 2007;357:2186-2188.
FULL TEXT
Adult Cystic Fibrosis
Boyle
JAMA 2007;298:1787-1793.
ABSTRACT
| FULL TEXT
Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis
Goss and Burns
Thorax 2007;62:360-367.
ABSTRACT
| FULL TEXT
Risk Factors for Death of Patients with Cystic Fibrosis Awaiting Lung Transplantation
Belkin et al.
Am. J. Respir. Crit. Care Med. 2006;173:659-666.
ABSTRACT
| FULL TEXT
Lung Transplantation: Disease-Specific Considerations for Referral
Nathan
Chest 2005;127:1006-1016.
ABSTRACT
| FULL TEXT
Ventilation Inhomogeneities in Relation to Standard Lung Function in Patients with Cystic Fibrosis
Kraemer et al.
Am. J. Respir. Crit. Care Med. 2005;171:371-378.
ABSTRACT
| FULL TEXT
Lung Function Decline in Cystic Fibrosis Patients and Timing for Lung Transplantation Referral
Rosenbluth et al.
Chest 2004;126:412-419.
ABSTRACT
| FULL TEXT
Indications, patient selection and timing of referral for lung transplantation
Glanville and Estenne
Eur Respir J 2003;22:845-852.
ABSTRACT
| FULL TEXT
Reply
Anyanwu and Murday
J. Thorac. Cardiovasc. Surg. 2003;125:1176-1176.
FULL TEXT
Cystic Fibrosis: When to Refer for Lung Transplantation-Is the Answer Clear?
Noone and Egan
Am. J. Respir. Crit. Care Med. 2002;166:1531-1532.
FULL TEXT
Developing Cystic Fibrosis Lung Transplant Referral Criteria Using Predictors of 2-Year Mortality
Mayer-Hamblett et al.
Am. J. Respir. Crit. Care Med. 2002;166:1550-1555.
ABSTRACT
| FULL TEXT
Patient Selection for Lung Transplantation
Maurer
JAMA 2001;286:2720-2721.
FULL TEXT
|